Recent Updates
Recently added Catalysts

FluBlok

Phase 3

Influenza | Monoclonal antibody | Infectious Disease |Sanofi|Trials Updated: Apr 6, 2022

FluBlok development status

Highest phase Phase 3
Registered trials 1 across 1 sponsor since Oct 2007

FluBlok target and mechanism

ModalityMonoclonal antibody

Also known as rHA Trivalent Recombinant Hemagglutinin Influenza Vaccine

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment4,648

FDA Designations

No designations recorded

FluBlok clinical trials

FluBlok · 1 trial · 1 indication

Phase 3 1
NCT00539981Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlokInfluenza
COMPLETED4,648 Analytics
PHASE3COMPLETED
Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok
InfluenzaUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants Reporting Solicited Injection Site (Local) Reactions
Within 7 days post vaccination

Solicited reaction (reactogenicity event) was an adverse event (AE) that was pre-listed in electronic case report form(eCRF), considered to be related to vaccination and recorded by participant by means of memory aid. Injection sites reaction included pain,bruising,redness,swelling. Pain and bruising:Grade0: didn't have it at all; Grade1: noticed it, but it didn't interfere with usual activities at all; Grade2: had it, and it was bad enough to prevent a significant part of usual activities; Grade3: had it, and it prevented most or all of normal activities, or had to see a doctor for prescription medicine, Redness and swelling: participants measured largest diameter of any injection site reaction and grade them from 0 to 3, where Grade0: measured less than(\<)10 milliliters(mm); Grade1: larger than or equal to(\>=) 10mm and \<20mm; Grade 2: \>=20mm and \<50mm; Grade3: \>=50mm. Participants with multiple symptoms in same category were counted once per category using symptom with maximum grade

Number of Participants Reporting Solicited Systemic Reactions
Within 7 days post vaccination

Solicited reaction (reactogenicity event) was an AE that was pre-listed in eCRF, considered to be related to vaccination recorded by the participant by means of a memory aid between the day of vaccination (Day 0) and Day 7 post vaccination. Systemic events included fever, fatigue, shivering, joint pain, muscle pain, headache, and nausea. Fever: \>=100.4 degree Fahrenheit (ºF) to \<101.1ºF; \>=101.2ºF to \<102.2ºF; \>=102.2ºF; Fatigue, shivering, joint pain, muscle pain, headache and nausea: Grade 0: didn't have it at all; Grade 1: noticed it, but it didn't interfere with usual activities at all; Grade 2: had it, and it was bad enough to prevent a significant part of usual activities; and Grade 3: had it, and it prevented most or all of normal activities, or had to see a doctor for prescription medicine. Participants with multiple symptoms in the same category were counted once per category using the symptom with the maximum grade.

Number of Participants Reporting Unsolicited Adverse Events
From Day 0 (post-vaccination) through Day 28 post vaccination

An AE was defined as any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a study vaccine, whether or not considered to be related to the study vaccine. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted (i.e., solicited) in the eCRF in terms of symptom and/or onset post-vaccination, ascertained during follow-up visit or telephone contact up to (and including) the Day 28 contact, whether reported spontaneously by the participant or in response to general questions about current or interim health status.

Lot Consistency: Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies Following FluBlok Vaccination
Day 28 post vaccination

GMTs of anti-influenza antibodies were measured using a single radial immunodiffusion (SRID) assay for 3 strains: A/Solomon Islands \[H1N1\], A/Wisconsin \[H3N2\], and B/Malaysia. Titers were expressed in terms of 1/dilution.

Percentage of Participants With Positive Cell Culture/Culture-Confirmed Influenza Like Illness as Defined by Centers for Disease Control and Prevention (CDC-ILI)
14 days post vaccination through and up to 6 months

CDC-defined ILI was defined as fever (body temperature \>=100ºF oral accompanied by cough and/or sore throat, on the same day or on consecutive days) due to strains represented in the vaccine.

Secondary Endpoints

Percentage of Participants With Seroprotection to Influenza Vaccine Antigens After Vaccination With FluBlok
28 days post vaccination
Percentage of Participants With Seroconversion to Influenza Vaccine Antigens After Vaccination With FluBlok
28 days post vaccination
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
FluBlok (Lots A, B, C)EXPERIMENTALParticipants received a single 0.5 milliliters (mL) dose of FluBlok vaccine from any of the Lots A, B, or C, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination.
PlaceboPLACEBO_COMPARATORParticipants received a single dose of placebo matched to FluBlok, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination.

Interventions

NameTypeDescription
FluBlok®BIOLOGICALDose: 0.5 mL, single dose; Route of administration: intramuscular. Recombinant Trivalent Hemagglutinin Influenza Vaccine containing 45 microgram (mcg) of each hemagglutinin derived from A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
PlaceboBIOLOGICALDose: 0.5 mL normal saline for injection, single dose; Route of administration: intramuscular
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 49 Years
SexALL
Healthy VolunteersYes
Study Sites24

Inclusion Criteria: * Healthy adult aged 18-49 years. * Provided informed consent prior to any study procedures. * Able to comply with all study procedures. * Available for follow-up for the duration of the influenza season. * Women of child-bearing potential must have had a negative urine pregnanc...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about FluBlok

What is FluBlok used for?

FluBlok is used for the prevention of influenza in adults. It is a vaccine developed by Sanofi, and its clinical program has studied its immunogenicity, safety, reactogenicity, efficacy, effectiveness, and lot consistency in healthy adult volunteers aged 18 years and older.

Who makes FluBlok?

FluBlok is made by Sanofi, which trades under the ticker SNY. Sanofi is the developer of the vaccine, and the clinical program for FluBlok has been conducted in the United States.

What phase is FluBlok in?

FluBlok has been studied in Phase 3 clinical development. The Phase 3 trial for FluBlok has been completed, and the program enrolled 4,648 participants. FluBlok is an investigational product in the context of the clinical development described here.

What clinical trials is FluBlok in?

FluBlok has been evaluated in the Phase 3 trial NCT00539981, titled Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok. This completed trial enrolled 4,648 participants in the United States, was randomized, double blind, and placebo controlled, and included healthy volunteers aged 18 years and older.

Is FluBlok the same as FluBlok®?

Yes, FluBlok and FluBlok® refer to the same vaccine. FluBlok® is the registered trademark form of the name, while FluBlok is the plain-text version used in scientific and regulatory contexts. Both names identify the Sanofi influenza vaccine.